Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.88 |
| ▸ | GSPT1 | P15170 | 14/20 | 0.88 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.78 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.78 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865843 | 1.00 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30865829 | 0.94 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29225896 | 0.94 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30865831 | 0.89 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29226100 | 0.89 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29360673 | 0.88 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL61575 | 0.88 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30865828 | 0.86 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL29225882 | 0.86 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL29225988 | 0.86 | CRBN (0.79) | CRBNGSPT1DDB1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917402-A | Isoindolylamide compound, and pharmaceutical composition and application thereof | 暨南大学 | 2024-04-23 | — | — | CN | disclosed |